| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H18N4O3S2 |
| Molecular Weight | 402.491 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C(=O)CC1=CC=C(C=C1)C2=NC=CC=C2)C3=NC(C)=C(S3)S(N)(=O)=O
InChI
InChIKey=IVZKZONQVYTCKC-UHFFFAOYSA-N
InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25)
| Molecular Formula | C18H18N4O3S2 |
| Molecular Weight | 402.491 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pritelivir is a thiazolylamide derivative patented by German multinational pharmaceutical and life sciences company Bayer A.-G. as helicase-primase enzyme inhibitor that is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). In preclinical Pritelivir was shown to be active when treatment was delayed to 72 h post viral inoculation and appeared to synergistically inhibit mortality in this model in combination with acyclovir. Pritelivir could be an alternative therapeutic agent for patients infected with acyclovir-resistant strains. Phase II clinical trials currently are ongoing.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 30.0 nM [IC50] |
